The use of Thiocetam in the complex therapy of combat-related brain contusion
DOI:
https://doi.org/10.14739/2409-2932.2023.2.281460Keywords:
nootropic agents, brain injuries, oxidative stress, neuroprotective agents, contusions, cognitive functionAbstract
Each patient presents a unique set of characteristics and challenges when it comes to acute cerebral ischemia resulting from craniocerebral injury.
The aim of this study is to investigate the utilization of Thiocetam as part of a comprehensive treatment approach for combat-related cerebral contusion and to assess the therapeutic effects of Thiocetam in patients with mild and moderate closed combat craniocerebral trauma in comparison to standard basic therapy.
Materials and methods. 79 patients with mild and moderate closed combat craniocerebral trauma were examined. Among them, 76 patients experienced craniocerebral trauma due to an explosive blast injury, which included conditions such as brain concussion, mild cerebral contusion, and cranial vault fractures. All patients were admitted to the department during the acute period of their injuries.
During the study, various clinical and functional methods were employed to assess the condition of the central nervous system. These methods were used to evaluate the effects of the complex treatment administered to the patients.
Results. The administration of Thiocetam to the patients did not result in an increase in excitability, nervousness, or sleep disturbances. Furthermore, the examination of autonomic reactivity following Thiocetam treatment revealed that the indicator of normal autonomic reactivity increased to 60 % in the treated group, whereas it only increased to 42 % in the control group. Additionally, the patients with initially heightened vegetative reactions experienced a decrease from 42.8 % to 17.9 % in the treated group, while the control group saw a decrease from 38.5 % to 23.1 %. In terms of clinical outcomes, a positive effect was observed in 94 % of patients in the Thiocetam-treated group within the first 5 days. In comparison, the control group showed a positive clinical effect in 76 % of cases. This improvement was evident both in the clinical field and based on indicators of autonomic reactivity in EEG data, as well as cognitive function assessed by the MMSE cognitive function test scale.
Conclusions. The utilization of Thiocetam during the acute phase of mild and moderate closed combat craniocerebral trauma enhances the neuroprotective effects of basic therapy. The combined drug Thiocetam, which possesses both nootropic and neuroprotective effects, offers the advantage of reducing or even avoiding the side effects commonly associated with traditional racetam nootropics.
References
Chernii, V. I., Andronova, M. A., Chernii, T. V., & Andronova, I. A. (2016). Doslidzhennia khronichnoi ishemii mozku za dopomohoiu metodu kilkisnoi elektroentsefalohrafii [Study of chronic brain ischemia using the method of quantitative electroencephalography]. Zhurnal nevrolohii im. B. M. Mankovskoho, 4(3), 43-49. [in Ukrainian].
Cherniy, V. I., Cherniy, T. V., & Andronova, I. A. (2019). Suchasni mozhlyvosti ta perspektyvy intensyvnoi terapii khvorykh iz hostrym ishemichnym insultom v Ukraini [Modern opportunities and prospects intensive therapy of patients with acute ischemic stroke in Ukraine]. Zhurnal nevrolohii im. B. M. Mankovskoho, 7(2), 5-14. [in Ukrainian].
Chernii, T., Fokina, D., & Chernii, V. (2020). Kompleksne likuvannia khvorykh z khronichnoiu ishemiieiu mozku. Tsilespriamovana korektsiia kohnityvnykh porushen ta vidnovlennia rukhovykh funktsii pislia perenesenoho mozkovoho insultu [Comprehensive treatment of patients with chronic brain ischemia. Purposeful correction of cognitive impairment and recovery of motor functions after a stroke]. Klinichna ta profilaktychna medytsyna, 4(14), 33-43. [in Ukrainian]. https://doi.org/10.31612/2616-4868.4(14).2020.02
Cherniy, V. I., & Cherniy, T. V. (2021). Suchasni pryntsypy diahnostyky y likuvannia tiazhkoi cherepno-mozkovoi travmy [Modern principles of diagnosis and treatment of severe traumatic brain injury]. Emergency medicine, 17(5), 6-12. [in Ukrainian]. https://doi.org/10.22141/2224-0586.17.5.2021.240700
Belenichev, I. F., Chekman, I. S., Nagornaya, E. A., Gorbacheva, S. V., Gorchakova, N. A., Bukhtiyarova, N. V., Reznichenko, N. Yu., & Feroz Shakh. (2020). Tiol-disulfidnaya sistema: rol v endogennoi tsito- i organoprotektsii, puti farmakologicheskoi modulyatsii [Thiol-Disulfide System: Role in Endogenous Cyto-and Organoprotection, Pathways of Pharmacological Modulation]. Kyiv : Yuston. [in Russian].
Belenichev, I., Kucherenko, L., Pavlov, S., Bukhtiyarova, N., Popazova, O., Derevianko, N., & Nimenko, G. (2022). Therapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline). Pharmacia, 69(2), 509-516. https://doi.org/10.3897/pharmacia.69.e82596
Reznichenko, Yu. H., Reznichenko, H. I., Borzenko, Yu. V., Smiian, O. I., Reznichenko, N. Yu., Bielenichev, I. F., Horchakova, H. O., Ryzhenko, O. I., & Siusiuka, V. H. (2020). Perynatalni urazhennia nervovoi systemy [Perinatal lesions of the nervous system]. Zaporizhzhia: Prosvita; 2020. [in Ukrainian].
Belenichev, I., Gorchakova, N., Kuchkovskyi, O., Ryzhenko, V., Varavka, I., Varvanskyi, P., & Gorova, E. (2022). Pryntsypy metabolitotropnoi terapii u pediatrychnii praktytsi. Kliniko-farmakolohichna kharakterystyka suchasnykh metabolitotropnykh zasobiv (chastyna 1) [Principles of metabolithotropic therapy in pediatric practice. Clinical and pharmacological characteristics of modern metabolithotropic agents (part 1)]. Fitoterapiia. Chasopys, (3), 6-26. [in Ukrainian]. https://doi.org/10.33617/2522-9680-2022-3-6
Belenichev I., Gorchakova N., KuchkovskyI O., Ryzhenko V., Varavka I., Varvanskyi P., & Gorova E. (2022). Pryntsypy metabolitotropnoi terapii u pediatrychnii praktytsi. Kliniko-farmakolohichna kharakterystyka suchasnykh metabolitotropnykh zasobiv (chastyna 2). [Principles of metabolithotropic therapy in pediatric practice. Clinical and pharmacological characteristics of modern metabolithotropic agents (part 2)].
Fitoterapiia. Chasopys, (4), 30-54. [in Ukrainian]. https://doi.org/10.33617/2522-9680-2022-4-30
Stammet, P. (2017). Blood Biomarkers of Hypoxic-Ischemic Brain Injury after Cardiac Arrest. Seminars in neurology, 37(1), 75-80. https://doi.org/10.1055/s-0036-1593858
Welch, R. D., Ellis, M., Lewis, L. M., Ayaz, S. I., Mika, V. H., Millis, S., & Papa, L. (2017). Modeling the Kinetics of Serum Glial Fibrillary Acidic Protein, Ubiquitin Carboxyl-Terminal Hydrolase-L1, and S100B Concentrations in Patients with Traumatic Brain Injury. Journal of neurotrauma, 34(11), 1957-1971. https://doi.org/10.1089/neu.2016.4772
Thelin, E. P., Nelson, D. W., & Bellander, B. M. (2017). A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta neurochirurgica, 159(2), 209-225. https://doi.org/10.1007/s00701-016-3046-3
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
